Single-dose intraoperative radiotherapy using Intrabeam® for early-stage breast cancer: a health technology assessment
Xie X, Dendukuri N, McGregor M
Record ID 32013000294
English
Authors' objectives:
Postoperative whole-breast external beam radiotherapy, usually delivering a dose of 42.56-50 Gy in 16-25 fractions over 4-5 weeks, reduces the risk of tumour recurrence and improves survival of breast cancer patients managed with breast-sparing surgery. Using a proposed newer treatment, single dose intraoperative radiotherapy (IORT), radiation is delivered to the tumour bed at the time of surgical excision without postoperative whole-breast external beam radiotherapy and boost for the selected patients with early-stage breast cancer. The objectives of the present report are to evaluate the effectiveness and safety of Intrabeam® radiotherapy for early-stage breast cancer and to estimate the budget impact of using this technology at the MUHC.
Authors' recommendations:
Proof of the non-inferiority of the Intrabeam® approach compared to conventional external beam irradiation rests on a single trial which has several weaknesses, including insufficient follow-up. None the less, the rates of local recurrence of breast cancer and rates of major complications appear to be comparable in the two arms of the trial.
From the perspective of MUHC, use of single dose Intrabeam® radiotherapy would slightly reduce or increase budget expenditure depending on turnover.
Its use would reduce the workload of the Radiation Oncology Department. From the perspective of patients, it would greatly reduce the inconvenience associated with weekly external beam radiation, and would reduce the waiting time for radiotherapy patients.
Use of this technology would cause an increased load on the Operating Room with the potential of increasing wait times for surgery.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
https://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_63_intrabeam.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Breast Neoplasms
- Intraoperative Care
- Radiotherapy, Adjuvant
Contact
Organisation Name:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address:
Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5
Contact Name:
nandini.dendukuri@mcgill.ca
Contact Email:
nandini.dendukuri@mcgill.ca
Copyright:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.